Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF, RAS, MSI-H/dMMR) and tumor location play a key role in guiding treatment selection. Immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) have recently emerged as novel options and will see robust uptake in eligible patients. Further personalization of treatment will ensure continued uptake of currently approved therapies over the 2020-2030 forecast period. We also expect several novel agents and combinations to impact the market and help address the high unmet need for additional and more-efficacious treatments.

QUESTIONS ANSWERED

  • How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
  • What are key opinion leaders’ views on current and emerging therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
  • Which pipeline products are poised to launch for colorectal cancer, and what unmet needs do they address?
  • What are the key drivers and constraints on the colorectal cancer therapy market, and how will the major markets evolve over the 10-year forecast period?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
      • Q3 2020
        • August 2020
    • Key Findings
      • Colorectal Cancer – Key Findings
        • August 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Colorectal Cancer: 2019
        • Market Share of Drug Classes for Colorectal Cancer: 2029
        • Drug-Treatable Population Share and Major-Market Sales Share in Colorectal Cancer: 2019
        • Drug-Treatable Population Share and Major-Market Sales Share in Colorectal Cancer: 2029
        • Population Positioning of Therapies in Colorectal Cancer
        • Colorectal Cancer SWOT Analysis
      • COVID-19: Areas of Potential Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Colorectal Cancer?
          • What Factors Are Constraining the Market for Colorectal Cancer?
          • Sales of Major Drug Classes, G7 (millions of U.S. dollars)
          • Major-Market Sales of Key Drugs by Brand/Biosimilar: 2019-2029
        • Segment-Specific Trends
          • Stage II/III Colorectal Cancer
          • Patient-Share Dynamics of Key Players in Stage III Colon Cancer, United States (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV First-Line, Left-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV First-Line, Right-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV First-Line, BRAF Wild-Type, RAS-Mutant Colorectal Cancer, U.S. (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV First-Line, BRAF-Mutant, RAS Wild-Type Colorectal Cancer, U.S. (2019-2029)
          • Second-Line Metastatic Colorectal Cancer
          • Patient-Share Dynamics of Key Players in Stage IV Second-Line, Left-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV Second-Line, Right-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV Second-Line, BRAF Wild-Type, RAS-Mutant Colorectal Cancer, U.S. (2019-2029)
          • Patient-Share Dynamics of Key Players in Stage IV Second-Line, BRAF-Mutant, RAS Wild-Type Colorectal Cancer, U.S. (2019-2029)
          • Third-Line Metastatic Colorectal Cancer
          • Patient-Share Dynamics of Key Players in Stage IV Third-Line, Left-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, United States: 2019-2029
          • Patient-Share Dynamics of Key Players in Stage IV Third-Line, Right-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, United States: 2019-2029
          • Patient-Share Dynamics of Key Players in Stage IV Third-Line, BRAF Wild-Type, RAS-Mutant Colorectal Cancer, United States: 2019-2029
          • Patient-Share Dynamics of Key Players in Stage IV Third-Line, BRAF-Mutant, RAS Wild-Type Colorectal Cancer, United States: 2019-2029
      • Forecast
        • Market Forecast Assumptions - Colorectal Cancer
        • Market Forecast Dashboard - Colorectal Cancer
      • Etiology & Pathophysiology
        • Disease Overview
          • Disease Pathophysiology
            • Etiology
            • Risk Factors for Developing Colorectal Cancer
            • Pathophysiology
            • Proposed Adenoma-Carcinoma Sequence Model for Colorectal Cancer with Chromosomal Instability
          • Staging and Classification
            • Staging of Colorectal Cancer
            • TNM Classification of Colorectal Cancer
            • Modified Astler-Coller Dukes Staging System vs. AJCC/UICC Colorectal Cancer (TNM) Staging System
            • Symptoms According to Tumor Location in Colorectal Cancer
            • Screening for Colorectal Cancer
            • Prognostic Factors in Colorectal Cancer
          • Key Pathways and Drug Targets
            • Drug Targets for Colorectal Cancer
            • Select Genes Reportedly Involved in Colorectal Cancer
        • Epidemiology
          • Key Findings
            • Key Updates
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of Colorectal Cancer
            • Diagnosed Incident Cases of Colorectal Cancer: 2019-2029
            • Disease Definition
            • Methods
            • Sources Used for Stage Distribution of Colorectal Cancer
            • Diagnosed Incident Cases of Colorectal Cancer by Stage Distribution: 2019-2029
            • Definition
            • Methods
            • Sources Used for Recurrent Incidence of Colorectal Cancer
            • Recurrent Incident Cases of Colorectal Cancer: 2019-2029
            • Colorectal Cancer Patient Flow
            • Drug-Treatable Cases of Colorectal Cancer: 2019-2029
            • Drug-Treated Cases of Colorectal Cancer: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Colorectal Cancer
            • Key Current Therapies
              • Overview
              • Mechanism of Action of Key Current Drug Classes Used for Colorectal Cancer
              • Current Treatments Used for Colorectal Cancer
              • Market Events Impacting the Use of Key Current Therapies in Colorectal Cancer
              • Advantages and Disadvantages of Avastin (Bevacizumab)
              • Key Results from Select Clinical Trials Investigating Avastin (Bevacizumab) for the Treatment of Colorectal Cancer
              • Expert Insight: Avastin (Bevacizumab)
              • Advantages and Disadvantages of Zaltrap
              • Key Results from Select Clinical Trials Investigating Zaltrap for the Treatment of Colorectal Cancer
              • Expert Insight: Zaltrap
              • Advantages and Disadvantages of Cyramza
              • Key Results from Select Clinical Trials Investigating Cyramza for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Cyramza
              • Key Ongoing Clinical Trials of Cyramza in the Treatment of Colorectal Cancer
              • Expert Insight: Cyramza
              • Advantages and Disadvantages of Stivarga
              • Key Results from Select Clinical Trials Investigating Stivarga for the Treatment of Colorectal Cancer
              • Expert Insight: Stivarga
              • Advantages and Disadvantages of Erbitux
              • Key Results from Select Clinical Trials Investigating Erbitux for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Erbitux
              • Key Ongoing Clinical Trials of Erbitux in the Treatment of Colorectal Cancer
              • Expert Insight: Erbitux
              • Advantages and Disadvantages of Vectibix
              • Key Results from Select Clinical Trials Investigating Vectibix for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Vectibix
              • Key Ongoing Clinical Trials of Vectibix in the Treatment of Colorectal Cancer
              • Expert Insight: Vectibix
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Keytruda
              • Expert Insight: Keytruda
              • Key Results from Select Clinical Trials Investigating Opdivo for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Opdivo
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of Colorectal Cancer
              • Expert Insight: Opdivo
              • Key Results from Select Clinical Trials Investigating Braftovi for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Braftovi
              • Key Ongoing Clinical Trials of Braftovi in the Treatment of Colorectal Cancer
              • Expert Insight: Braftovi
              • Advantages and Disadvantages of Lonsurf
              • Key Results from Select Clinical Trials Investigating Lonsurf for the Treatment of Colorectal Cancer
              • Ongoing Clinical Development of Lonsurf
              • Key Ongoing Clinical Trials of Lonsurf in the Treatment of Colorectal Cancer
              • Expert Insight: Lonsurf
            • Medical Practice
              • Stage II/III Colon Cancer
              • Stage II/III Rectal Cancer
              • Treatment of Colorectal Cancer with Resectable Liver Metastases
              • Second-Line Treatment of Metastatic Colorectal Cancer
              • Third- and Later-Line Treatment of Metastatic Colorectal Cancer
              • Patient Characteristics Influencing Drug Selection in Colorectal Cancer
              • Treatment Decision Tree for Stage II/III Colon and Rectal Cancer: G7
              • Treatment Decision Tree for Stage IV Colorectal Cancer: United States
              • Treatment Decision Tree for Stage IV Colorectal Cancer: France, Germany, Italy, and Spain
              • Treatment Decision Tree for Stage IV Colorectal Cancer: United Kingdom
              • Treatment Decision Tree for Stage IV Colorectal Cancer: Japan
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in Colorectal Cancer
            • Top Unmet Needs in Colorectal Cancer: Current and Future Attainment
            • Expert Insights: Unmet Need in Colorectal Cancer
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Key Therapies in Development for Colorectal Cancer
                • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Fruquintinib for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Fruquintinib in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Fruquintinib
                • Expert Insight: Fruquintinib
                • Expectations for Market Authorization and Sales Opportunity of Fruquintinib in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Lenvima for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Lenvima in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Lenvima
                • Expectations for Market Authorization and Sales Opportunity of Lenvima in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Adagrasib for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Adagrasib in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Adagrasib
                • Expectations for Market Authorization and Sales Opportunity of Adagrasib in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Tecentriq
                • Expert Insight: Tecentriq
                • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Colorectal Cancer
                • Key Ongoing Clinical Trials of Bavencio in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Bavencio
                • Expert Insight: Bavencio
                • Expectations for Market Authorization and Sales Opportunity for Bavencio in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Imfinzi
                • Expert Insight: Imfinzi
                • Expectations for Market Authorization and Sales Opportunity for Imfinzi in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating OncoVax for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of OncoVax in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for OncoVax
                • Expert Insight: OncoVax
                • Expectations for Market Authorization and Sales Opportunity for OncoVax in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Napabucasin for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Napabucasin in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Napabucasin
                • Expectations for Launch and Sales Opportunity of Napabucasin in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Modufolin for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Modufolin in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Modufolin
                • Expectations for Market Authorization and Sales Opportunity of Modufolin in Colorectal Cancer
                • Key Results from Select Clinical Trials Investigating Lynparza for the Treatment of Colorectal Cancer
                • Key Ongoing Clinical Trials of Lynparza in the Treatment of Colorectal Cancer
                • Analysis of the Clinical Development Program for Lynparza
                • Expert Insight: Lynparza
                • Expectations for Market Authorization and Sales Opportunity of Lynparza in Colorectal Cancer
              • Early-Phase Pipeline Analysis
                • Select Compounds in Early-Phase Development for Colorectal Cancer
            • Access & Reimbursement Overview
              • Region-Specific Reimbursement Practices
                • Key Market Access Considerations in Colorectal Cancer: United States
                • General Reimbursement Environment: United States
                • Key Market Access Considerations in Colorectal Cancer: EU5
                • General Reimbursement Environment: EU5
                • Key Market Access Considerations in Colorectal Cancer: Japan
                • General Reimbursement Environment: Japan
            • Appendix
              • Colorectal Cancer Bibliography

          Author(s): Fiona Wiegert; Mudasir Khan, M.P.H.

          Fiona Wiegert, M.Sc., is a business insights analyst on the Oncology team at Clarivate. She has a background in market research and analysis within the pharmaceutical industry and experience in several oncology indications. Previously, she worked on product-specific business cases and forecast models at Accord Healthcare. She earned a master’s degree in cognitive neuroscience from the University of Sussex and was awarded the prize for best performance on this course.

          Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai.


          Related Reports

          Colorectal Cancer | Disease Landscape and Forecast | G7 | 2020

          Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented...

          View Details

          Colorectal Cancer - Geographic Focus: China - Colorectal Cancer - China In-Depth (China)

          Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

          View Details

          Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

          This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

          View Details